A pilot program in the U.K. that takes selected compounds from pharmaceutical companies’ back catalogues and gathers ideas on their potential scientific use and possible commercial development is being expanded.
The repurposing scheme, begun in 2011 and piloted by AstraZeneca PLC and the U.K.’s Medical Research Council (MRC), is...